172 assets in Refractory Malignant Neoplasm

Therapeutic assets addressing Refractory Malignant Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ivuxolimab Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (45)
Methoxyamine Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CC (45)
Onivyde Refractory Malignant Neoplasm	St. Jude Children's Research Hospital	P1/2	CC (45)
Retifanlimab Refractory Malignant Neoplasm	OHSU Knight Cancer Institute	P1/2	CC (45)
Tegavivint Refractory Malignant Neoplasm	Children's Oncology Group	P1/2	CC (45)
Everolimus Refractory Malignant Neoplasm	OHSU Knight Cancer Institute	P1	CC (44)
Utomilumab Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (44)
177lu-ab-3prgd2 radioligand therapy Refractory Malignant Neoplasm	The First Affiliated Hospital of Xiamen University	P1	CC (43)
[177lu]lu-sn201 Refractory Malignant Neoplasm	Spago Nanomedical AB	P1/2	CC (43)
Bgb-16673 Refractory Malignant Neoplasm	BeOne Medicines	P1/2	CC (43)
Cid-078 Monotherapy Refractory Malignant Neoplasm	Circle Pharma	P1	CC (43)
do-2 Refractory Malignant Neoplasm	DeuterOncology	P1	CC (43)
Fluorouracilum Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1	CC (43)
Hst-1011 Refractory Malignant Neoplasm	HotSpot Therapeutics, Inc	P1/2	CC (43)
Hydroxyurea Refractory Malignant Neoplasm	Bionoxx Inc.	P1	CC (43)
Ibrutinib Refractory Malignant Neoplasm	Dana-Farber Cancer Institute	P1/2	CC (43)
ic9-car.b7-h3 t cells Refractory Malignant Neoplasm	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
ic9-car.b7-h3 t cell therapy Refractory Malignant Neoplasm	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
il-22bp Refractory Malignant Neoplasm	West China Hospital	P1	CC (43)
il-22bp mrna vaccine Refractory Malignant Neoplasm	Xingchen Peng	P1	CC (43)
ima402 Refractory Malignant Neoplasm	Immatics Biotechnologies GmbH	P1/2	CC (43)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Refractory Malignant Neoplasm	BeOne Medicines	P1/2	CC (43)
Immunoglobulin G4(228-Proline), Anti-(Human Cd47 Antigen) (Human Monoclonal Sti-6643 .Gamma.4-Chain), Disulfide With Human Monoclonal Sti-6643 .Kappa.-Chain, Dimer Refractory Malignant Neoplasm	Sorrento Therapeutics, Inc.	P1	CC (43)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Refractory Malignant Neoplasm	Sensei Biotherapeutics, Inc.	P1/2	CC (43)
Itraconazole Refractory Malignant Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1	CC (43)
LXP1788 Refractory Malignant Neoplasm	LaunXP Biomedical Co., Ltd.	P1	CC (43)
Mosunetuzumab Refractory Malignant Neoplasm	BeOne Medicines	P1/2	CC (43)
nkg2d-car-nk92 cells Refractory Malignant Neoplasm	Henan Medical University	P1	CC (43)
Obinutuzumab Refractory Malignant Neoplasm	BeOne Medicines	P1/2	CC (43)
Ots-412 Refractory Malignant Neoplasm	Bionoxx Inc.	P1	CC (43)
Paxalisib Refractory Malignant Neoplasm	Australian & New Zealand Children's Haematology/Oncology Group	P1/2	CC (43)
Pimitespib Refractory Malignant Neoplasm	Brown University	P1	CC (43)
qlc5508 Refractory Malignant Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1	CC (43)
Rifaldazine Refractory Malignant Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1	CC (43)
Solnerstotug Refractory Malignant Neoplasm	Sensei Biotherapeutics, Inc.	P1/2	CC (43)
Sonrotoclax Refractory Malignant Neoplasm	BeOne Medicines	P1/2	CC (43)
Cbl-0137 Free Base Refractory Malignant Neoplasm	Children's Oncology Group	P1/2	CC (42)
Anti-Meso Car T Cells Refractory Malignant Neoplasm	Ruijin Hospital	P1	CC (41)
au409 Refractory Malignant Neoplasm	University of Southern California	P1	CC (41)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Refractory Malignant Neoplasm	Anusha Kalbasi	P1	CC (41)
Darolutamide Refractory Malignant Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1	CC (41)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Refractory Malignant Neoplasm	Anusha Kalbasi	P1	CC (41)
Neratinib Refractory Malignant Neoplasm	OHSU Knight Cancer Institute	P1	CC (41)
Pcna Inhibitor Aoh1996 Refractory Malignant Neoplasm	City of Hope Medical Center	P1	CC (41)
Riluzole Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
scd1 inhibitor mti-301 Refractory Malignant Neoplasm	Mayo Clinic	P1	CC (41)
Tak-243 Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Adu-1805 Refractory Malignant Neoplasm	Sairopa B.V.	P1	C (39)
Allogeneic Nkg2Dl-Targeting Chimeric Antigen Receptor-Grafted Γδ T Cells Refractory Malignant Neoplasm	CytoMed Therapeutics Pte Ltd	P1	C (39)
Avutometinib Refractory Malignant Neoplasm	Memorial Sloan Kettering Cancer Center	P1	C (39)

Showing 101 to 150 of 172 assets

PreviousPage 3 of 4Next